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CASE PRESENTATION
A 50-year-old African American man came to the emer-
gency room complaining of substernal chest discomfort over
the past 2 months, as well as anorexia, general malaise, and
decreased urinary frequency over the past 2 weeks. The patient
stated that his chest pain lasted 2 to 3 minutes; did not radiate
to the neck, jaw, or shoulder; was precipitated by lifting heavy
objects; and did not occur at rest. He admitted to mild shortness
of breath when walking up the stairs at home. He noted that
for 2 weeks, he had been feeling exhausted and had had poor
appetite, weight loss, and less frequent urination than usual.
The patient had last seen a physician 4 years ago at an urgent
care facility for a pilonidal cyst abscess. Five years prior to
that, he had been told by a primary care physician that he had
hypertension. He was treated with an unknown medication
and, after a follow-up visit, was told that his blood pressure
was normal. He has no other known history of cardiovascular
or renal disease. He takes no medications.
He lost his job as a cook and the health insurance that the
job provided; he now says that he is unable to continue seeing
the physician. He completed high school, is married, and works
as a taxi driver as well as at a local farmers market on weekends.
His father had hypertension and died suddenly at age 55. His
mother is 71 and has diabetes. He has one older brother who
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has hypertension, a younger brother with no apparent medical
problems, and one older sister with recent-onset diabetes. He
has one son, age 27, and one daughter, age 29, both of whom
are well.
Physical examination disclosed a pleasant, slightly overweight
black male. His height was 5 feet, 10 inches; his weight was 199
pounds. His blood pressure was 182/116 mm Hg; heart rate,
88 beats/min; respirations, 26 breaths/min; and temperature,
37C. Funduscopic examination revealed grade 2 arteriolar nar-
rowing. His lungs had crackles at both bases; cardiovascular
examination showed brisk carotid upstrokes, an S4 gallop, no
pericardial rub, and no jugular venous distention. The abdomi-
nal examination showed mild obesity, no hepatosplenomegaly,
and no abdominal bruit. Extremities showed trace pedal edema.
Neurologic examination revealed mild asterixis but otherwise
was unremarkable.
Laboratory examination revealed sodium, 135 mmol/L; potas-
sium, 6.4 mmol/L; chloride, 102 mmol/L; and bicarbonate, 15
mmol/L. The blood urea nitrogen (BUN) was 106 mg/dL; serum
creatinine, 13 mg/dL; glucose, 96 mg/dL; and total cholesterol,
210 mg/dL. Complete blood count was hemoglobin, 10.2 g/dL;
white blood cell count, 6500 mm3; and platelets, 176,000/mm3.
Serum albumin was 3.7 g/dL; calcium, 8.2 mg/dL; and phos-
phate, 6.8 mg/dL. Urinalysis revealed 3 protein and no glucose;
sediment showed 1 white blood cell and 2 red blood cells per
high-powered field and numerous hyaline casts. An electrocar-
diogram (EKG) showed normal sinus rhythm; heart rate, 80
beats/min; and left-ventricular hypertrophy by voltage criteria.
A chest radiograph disclosed prominent vasculature, small bi-
lateral pleural effusions, clear lung fields, and normal heart size.
The patient was admitted to the cardiac step-down unit.
Serial cardiac enzymes and EKGs showed no evidence of an
acute myocardial infarction. Echocardiogram showed a hyper-
trophic left ventricle with an ejection fraction of 60%. A tempo-
rary central venous dialysis catheter was placed, and the patient
underwent emergency hemodialysis. On day 3 of hospitaliza-
tion, his follow-up blood pressure was 160/95 mm Hg, a second
chest radiograph showed resolution of pleural effusions, and
his potassium level was 4.6 mmol/L. A complete serologic eval-
uation, searching for causes of renal disease other than hyper-
tension, was negative, including HIV, hepatitis B, and hepatitis
C panels. A serum protein immunoelectrophoresis and urine
protein immunoelectrophoresis did not show any monoclonal
gammopathy. He had no evidence of iron deficiency; intact para-
thyroid hormone (iPTH) was increased to 365 pg/mL. A 24-hour
urine collection contained 1.5 g protein, and the glomerular
filtration rate (GFR) (by creatinine clearance) was estimated to
Nephrology Forum: Health care disparities in chronic kidney disease764
be 8.7 mL/min. Renal ultrasound showed a left kidney measuring
10.1 cm and a right kidney measuring 10.3 cm with increased
echogenicity and no hydronephrosis. Renal biopsy showed fea-
tures consistent with advanced hypertensive nephrosclerosis.
An exercise thallium test revealed a 1.5 mm ST depression in
the anterior leads and a transient perfusion defect in the ante-
rior wall. Cardiac catheterization revealed an 80% stenosis in
the left anterior descending coronary artery. The patient had
successful angioplasty and was discharged home 5 days after
admission. His medications included a beta blocker, aspirin,
multivitamin, phosphate binders, vitamin D, iron supplements,
and intravenous erythropoietin on hemodialysis treatment days.
He was referred to a local hemodialysis facility. Four weeks
later, he received a left forearm polytetrafluoroethylene (Gore-
Tex) graft without complication. He returned to his work on
days he did not undergo dialysis until he received notification
of his eligibility for both Medicare and disability payments.
On initiation of hemodialysis treatment, the patient discussed
cadaveric transplantation with his physicians but did not un-
dergo a pretransplant evaluation and was not placed on the
waiting list for a cadaveric transplant. There was no discussion
about living-related kidney transplantation.
Aside from two mild episodes of skin infection at the vascular
access site managed easily with antibiotics, and a second admis-
sion 2 years later for an unsuccessful repeat angioplasty fol-
lowed by uneventful coronary artery bypass graft surgery, his
clinical course has remained unremarkable for 4 years.
DISCUSSION
Dr. Neil R. Powe (Director, Welch Center for Preven-
tion, Epidemiology and Clinical Research, Johns Hopkins
Medical Institutions; Professor of Medicine, Johns Hop-
kins University School of Medicine; and Professor of
Epidemiology and Health Policy and Management, Johns
Hopkins Bloomberg School of Public Health, Baltimore,
Maryland, USA): The patient presented today illustrates
many of the challenges involved in providing health care
to an ethnically diverse population of patients in the
United States. This man presented to an emergency room
with a subacute coronary syndrome and profound renal
insufficiency. He had not had the opportunity for early
intervention to delay progression of chronic kidney dis-
ease or to prepare for eventual renal replacement ther-
apy. Lack of health insurance coupled with the silent
nature of hypertension and chronic renal insufficiency
are major culprits in the late presentation to medical
care for individuals with known risk factors for chronic
renal disease. There is little opportunity to attend early
to comorbid conditions occurring before end-stage renal
disease (ESRD), including coronary artery disease, hy-
pertension, anemia, and hyperlipidemia. Decisions about
the choice of renal replacement therapy must be made in
an accelerated fashion. This haste raises concerns about
whether the health care providers, the patient, and the
family have adequately considered the different treat-
ment options. This case also illustrates the special plight
of African American patients, whose risk factors make
them more likely to develop progressive renal insuffi-
ciency and who are less likely to receive peritoneal dial-
ysis or undergo renal transplantation.
I will discuss the significant problem of health care
disparities existing in the midst of an epidemic of chronic
renal disease. I also will present current work being done
to understand the nature and origin of health disparities
that occur at many points during the evolution of chronic
kidney disease. Most of the work to date involves African
Americans, although similar problems likely exist for
other ethnic minorities as well. A better understanding
of what drives disparities in health status and in health
care will allow us to develop and implement specific and
successful interventions.
Inequalities in health and burden of renal disease
Recent research has uncovered a hidden epidemic of
racial inequalities for life expectancy, infant mortality,
and cause-specific mortality and morbidity in relation to
many diseases in the United States [1]. Chronic renal
disease is among the conditions that have a dispropor-
tionate impact on ethnic minorities in the United States.
The potential reasons for racial and ethnic inequalities
in health are multifactorial and include biologic (for ex-
ample, genetic), socioeconomic, environmental, psycho-
social, and cultural factors, as well as health risk behav-
iors, including life-style choices. Access to and quality
of health care also have an important impact on health
and are factors that are under the purview of physicians,
including nephrologists. To eliminate racial disparities,
physicians must understand the barriers to health and
health care that disproportionately affect many minority
communities. The barriers can occur outside the health
care environment (for example, lack of availability of
healthy food in certain neighborhoods) and also within
the health care environment at the level of patients,
providers, or the system.
The growing awareness of the epidemic of disparities
in health and health care in the United States coincides
with recognition of an epidemic of chronic renal disease.
The number of cases of ESRD in the United States
grew from less than 50,000 patients in 1974 to more
than 375,000 cases in 2000 [2]. More than 95,000 people
developed ESRD in the United States in 2000 [2]. Recent
efforts at creating a classification system for staging
chronic renal disease have provided estimates of the
number of people with more than mild renal damage;
that number is estimated to be 8 million to 20 million
[3, 4]. Projections suggest that the number of ESRD
patients in the United States will double over the first
decade of this century [5], and chronic renal disease is
receiving attention as a new public health imperative [5].
The course of a person who develops chronic kidney
disease progresses from having risk factors (and oppor-
tunities for primary prevention), to the initiation and
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Fig. 1. Course of illness in patients with chronic
renal disease. Abbreviations are: ESRD, end-
stage renal disease; CVD, cardiovascular dis-
ease.
progression of disease (and opportunities for secondary
prevention), to treatment, and finally to outcome. Unfor-
tunately, the epidemics of chronic kidney disease and
health disparities among ethnic minorities are intertwined.
I will illustrate the specific points along the course of
the patient with chronic kidney disease (Fig. 1), show
where such disparities exist, and describe what is being
done to better understand them.
The growing burden of chronic kidney disease is expe-
rienced disproportionately by ethnic minorities, as has
been well documented for more than a decade [6]. In
1999, the rate of ESRD attributed to hypertension was
sixfold higher for African Americans than whites, 319
cases per million compared to 52 cases per million, re-
spectively [2]. The rate of ESRD attributed to hyperten-
sion was nearly twofold higher for Asian and Native Ameri-
cans compared to whites. For ESRD attributed to diabetes,
the rate was five and one-half times greater for Native
Americans (520 cases per million) than for whites (95
cases per million), fourfold greater for African Ameri-
cans (419 cases per million), and almost twofold greater
for Asian Americans (182 cases per million). As illus-
trated by today’s patient, the mean age at onset for ESRD
is 5 years earlier for African Americans than for whites.
Only recently have studies attempted to elucidate the
reasons for such disparities. Familial aggregation of renal
disease has been reported [7–9]. Genetic factors might
play a role in disease causation or progression. Several
candidate genes associated with ESRD have been identi-
fied, including angiotensin-converting enzyme (ACE) in-
sertion/deletion, angiotensinogen M 235T, aldose reduc-
tase, G protein, and several other polymorphisms [10, 11].
More research is needed to confirm early, small studies
of these genetic associations and their contributions to
the entire growing burden of chronic renal disease.
A prospective study of 300,645 white and 20,222 black
men screened for enrollment in the Multiple Risk Factor
Intervention Trial showed over 16 years of follow-up that
for each of several levels of systolic blood pressure, Afri-
can American men were more likely to develop ESRD
than were white men [12]. An age-adjusted 3.2-fold greater
relative risk of developing ESRD for African Americans
versus whites was reduced to 1.9-fold after adjustment
for differences between African Americans and whites
in blood pressure, income, and risk factors such as choles-
terol, cigarette smoking, diabetes, and history of myocar-
dial infarction. A recent nationally representative, pro-
spective study of 9082 adult men and women, ages 30 to
74, enrolled in the Second National Health and Nutrition
Examination Survey II examined the cumulative inci-
dence of chronic kidney disease by linking data from
baseline interviews, physical examinations, and labora-
tory tests performed at baseline from 1976 to 1980 with
the Medicare ESRD registry and the National Death
Index [13]. This study examined whether socioeconomic
status, lifestyle, or clinical factors would explain the ex-
cess incidence of chronic kidney disease among African
Americans. Eleven percent of the excess risk was ac-
counted for by socioeconomic status, 24% by lifestyle
factors, and 32% of by clinical factors such as control of
blood pressure. All three factors combined accounted
for more than 40% of the excess risk (Fig. 2).
A similar study of diabetic renal disease in 1434 dia-
betic adults in four United States communities examined
factors that might explain why African Americans com-
pared to whites have an age- and gender-adjusted three-
and-one-half-fold higher risk of early renal function de-
cline during 3 years of follow-up (defined as an increase
in serum creatinine of 0.4 mg/dL) [14]. The relative odds
of early renal function decline decreased by 15% when
health behaviors were taken into account, by 45% when
physiologic factors were taken into account, by 52%
when socioeconomic status was taken into account, and
by 83% when all three factors were combined. These
studies suggest that genetic factors are not the predomi-
nant reason for the greater burden of renal disease among
minorities, at least among African Americans, and pro-
vide attractive targets for interventions.
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Fig. 2. Risk of chronic kidney disease in blacks
versus whites. Abbreviations are: SES, socio-
economic status; BMI, body mass index; ETOH,
alcohol; HTN, hypertension; DM, diabetes
mellitus; CVD, cardiovascular disease; SBP,
systolic blood pressure (modified from refer-
ence 13).
Access to medical care
For some chronic diseases such as coronary heart dis-
ease, numerous studies have suggested that minorities
are less likely to receive intensive, life-saving technology
[15–17]. Data from the early experience of the ESRD
program show how the social and demographic charac-
teristics of the United States hemodialysis population
changed after the institution of the Medicare ESRD pro-
gram [18]. A study by Evans et al suggested that health
insurance for renal replacement therapy increased access
to treatment for women, African Americans, the less-
educated, and unmarried individuals [18]. A recent study
examining the relative odds of treatment for ESRD in
African Americans versus whites in the general popula-
tion over 16 years of follow-up suggests even more
strongly that no difference exists in access to treatment
with renal replacement therapy (dialysis or transplanta-
tion) between these racial groups [19].
Despite evidence that access to renal replacement
therapy is similar between African Americans and whites,
studies suggest that African Americans (as well as His-
panic and older patients) are evaluated later in the course
of progression of chronic renal disease [20, 21]. In one
national study, 45% of African American males were
evaluated by a nephrologist less than 4 months before
the start of dialysis compared to 25% of white males, 30%
of white females, and 38% of African American females
[21]. As with today’s patient, late timing of evaluation
for renal impairment can lead to excess morbidity and
leaves little time for preparation for dialysis, including
establishment of vascular access, discussions about treat-
ment options, treatment of comorbid disease such as ane-
mia, and initiation of adjunct therapies such as erythro-
poietin therapy [22]. In the same study, patients who were
evaluated later by a nephrologist had a greater severity
of comorbid disease, were older, and lacked health insur-
ance.
Atherosclerotic cardiovascular disease and its risk fac-
tors are more prevalent in patients with chronic kidney
disease than in the general population [23–32]. Our pa-
tient had a number of risk factors for cardiovascular
disease. Data from a study of cardiovascular disease in
patients with chronic kidney disease lends additional cre-
dence to the role of insurance in affecting access to ther-
apy. A retrospective cohort study of 3152 randomly se-
lected adult white and 1835 randomly selected adult
African American patients with chronic kidney disease
showed that prior to the development of ESRD, the
relative odds of the patient undergoing a cardiovascular
procedure (cardiac catheterization, percutaneous trans-
luminal coronary angioplasty, or coronary artery bypass
graft surgery) were more than threefold greater for
whites than for African Americans [33]. After develop-
ment of ESRD in patients who had Medicare insurance
coverage, whites were no more likely than blacks to
receive a cardiovascular procedure. Among initially un-
insured persons, rates of cardiovascular procedures after
enrollment in the Medicare program rose most among
black men, followed by black women, and white women
[34]. Interestingly, in this study, rates of cardiovascular
procedures among uninsured white men with ESRD de-
creased slightly after these men acquired Medicare insur-
ance. Among privately insured patients, procedure rates
for black men, black women, and white women also
increased after acquiring Medicare insurance, but the
increases were smaller. But cardiovascular procedures
among privately insured white men decreased consider-
ably (Fig. 3). The equalization of cardiovascular proce-
dure rates cannot be ascribed solely to differences in
insurance coverage, because even among persons who
had Medicare coverage prior to development of ESRD,
gaps in procedure rates occurred prior to development of
ESRD and were eliminated after development of ESRD.
This latter finding suggests that development of a chronic
disease for which regular medical care is needed for life-
saving renal replacement therapy also might influence
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Fig. 3. Rates of cardiovascular procedure use among chronic kidney
disease patients who were privately insured prior to development of
end-stage renal disease (ESRD). (Reprinted with permission from refer-
ence 34.)
whether ethnic minorities receive adequate care. Fur-
thermore, the decreases in cardiovascular procedures
among white ESRD patients who were uninsured or
privately insured but who then obtain Medicare coverage
raise the possibility of an earlier inappropriate use of
technology.
Dialysis. Studies have shown that African Americans
are as much as 56% less likely to receive peritoneal dialysis
than hemodialysis [35, 36]. This finding is true even when
differences in age, education, social support, wealth, func-
tional status, and clinical factors between African Ameri-
cans and whites are taken into account [35]. Evidence
from patients with other diseases suggests that some physi-
cians tend to perceive minorities and members of low
and middle socioeconomic groups more negatively than
their majority or upper socioeconomic class counterparts
on a number of dimensions that one might deem impor-
tant for peritoneal dialysis, including patient intelligence,
beliefs about patients’ likelihood of risky behavior, and
adherence to medical advice [37, 38]. However, a study
of physician behavior using standardized patient descrip-
tions suggests that the observed differences in treatment
modality by race are not due to physician prescribing be-
havior when compliance with treatment and other factors
are explicitly taken into account [39]. With innovations
in dialysis care, such as daily and nocturnal home dialysis,
disparities in access to technology should be monitored
to determine whether racial and gender equality result.
Racial differences in the quality of dialysis care have
been observed. In 1994, data from the core indicator
project conducted by the Center of Medical and Medic-
aid Services (CMS) showed that 60% of African Ameri-
cans on dialysis received an “inadequate” dose of dialysis
(as defined by process, not outcome measures). Al-
though evidence suggests that this percentage has de-
creased over time, in 1997 African Americans still had
a 20% chance of receiving inadequate dialysis [40–42].
Blacks do, however, have a survival advantage on dialytic
therapy. For patients with ESRD on dialysis, lives are
short (5-year survival of less than 50%) and quality of
life is diminished in terms of both physical and mental
function [43–47]). At variance with the general popula-
tion, African Americans with ESRD on dialysis live
longer than their majority counterparts. Today’s patient
has survived more than 5 years. Several reasons for this
greater survival on dialysis have been explored, including
less receipt of renal replacement therapy for African
Americans with more-severe versus less-severe comor-
bidity and selection of healthier patients for transplant
among African Americans versus whites [48]. However,
the reasons remain elusive.
While a survival advantage exists for African Ameri-
cans, African Americans do not necessarily receive all
the benefits of modern renal care and subsequently enjoy
less-than-optimal outcomes. In one study of the impact
of late referral to a nephrologist, the impact of late refer-
ral on mortality was greater among blacks than whites
and among diabetics than nondiabetics with chronic re-
nal failure [21]. Blacks as well as whites who receive
renal transplants live longer than their counterparts who
do not receive transplants.
Renal transplantation. Renal transplantation offers
ESRD patients an opportunity to return to a quality of
life reminiscent of life before they had ESRD. However,
the waiting list for a kidney continues to grow as more
patients develop ESRD and the supply of donor kidneys
remains relatively constant. In 2000, 47,831 people were
on the waiting list for kidneys [49]; in contrast, 13,258
kidneys from 10,565 donors were transplanted in the
same year. Disparities among ethnic groups in trans-
plantation rates have been noted for at least two decades
[50–54]. One might question why our patient did not
proceed on a path to organ transplantation. The reasons
for racial differences in access to transplantation have
recently become apparent. These include patient prefer-
ences, suitability, and appropriateness of patients for
transplantation, availability of organs, and system barri-
ers impeding the required medical workup.
Alexander and Sehgal examined the barriers to renal
transplantation among blacks, women, and the poor in a
cohort study of 7125 patients beginning dialysis between
1993 and 1997 in Indiana, Ohio, and Kentucky [55]. They
examined whether patients had successfully completed
each of four separate steps toward transplantation: (1)
being medically suitable and possibly interested in receiv-
ing a transplant, (2) being definitely interested in receiv-
ing a transplant, (3) completing the pretransplantation
workup and being placed on the waiting list, and (4) moving
up on the waiting list and receiving a transplant. They
found that although African Americans were equally
likely as whites to be medically suitable and possibly inter-
ested in a transplant, blacks were less likely to be definitely
interested. Also, African Americans were less likely to
complete the pretransplant workup and be placed on the
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waiting list, and less likely to move up on the waiting
list and receive a transplant. Ayanian also found that
African American women and men were less likely than
their white counterparts to want to receive a transplant
and be very certain about their preferences to receive a
transplant [56]. In short, even when preferences were
accounted for, blacks were still less likely than whites to
undergo transplantation. These data are consistent with
those from the midwestern United States study showing
that disparities occur at multiple stages of the process
[55]. In the case presented today, discussion occurred
between the patient and his physicians regarding trans-
plantation, but we have little information about the qual-
ity of the communication, how participatory the interac-
tions were between patient and physician, and whether
subtle biases, stereotyping, or system factors contributed
to the patient not going forward with renal transplanta-
tion. Recent work raises the possibility that intervening
in a patient’s social network as well as patient-physician
communication, including participatory decision-mak-
ing, also can influence interest in transplantation [57–59].
A national cohort study suggests that access to the wait-
ing list for kidneys has not improved for adult patients
over time despite recognition of the problem; for African
Americans this trend might be worsening [60]. Even more
troubling is evidence suggesting that those who are the
most appropriate candidates for transplantation, that is,
patients without comorbid conditions and those who are
younger, are the least likely to gain access to waiting lists.
Among children, wait list rates are 20% less for African
American than white children [61].
In an illuminating study, Epstein showed that among
patients who were judged clinically appropriate for trans-
plantation, African Americans were only slightly less
likely to be referred for transplantation and placed on
the waiting list but were much less likely to receive a
transplant [62]. Among clinically inappropriate transplant
candidates, white patients were more likely than African
Americans to be referred for transplantation, placed on
the waiting list, and receive a transplant [62]. This latter
situation is reminiscent of the aforementioned use of
cardiovascular procedures in privately insured patients.
The distribution of histocompatibility locus antigen
matches in transplanted cadaveric kidneys is worse
among African Americans than whites [63]. This factor
probably contributes substantially to the worse graft sur-
vival in blacks. One might surmise that because graft
survival for African Americans is worse than for whites,
and survival on dialysis is greater for African Americans
than whites, less transplantation in African Americans
might be appropriate. However, with modern advances
in immunosuppression, the differences in survival times,
stratified for the number of transplant mismatches, have
narrowed over time [57, 58], and the combined survival
and quality-of-life benefits of transplantation in African
Americans should dominate these other considerations.
Racial disparities in the supply of donor kidneys. Ca-
daveric kidney donation rates vary substantially by race
[2, 64, 65]. Rates are higher for whites than for African
Americans and are lowest for Asians and Native Ameri-
cans [2]. In contrast, living related donation rates for
African Americans are similar to those for whites [2].
Our patient has siblings, some with and another without
risk factors for chronic kidney disease. Low rates of
cadaveric donation among blacks, which lead to a more
select pool of histocompatibility locus antigens among
donated kidneys, have been cited as one reason for poorer
transplant survival among African Americans. A recent
study exploring the combined effect of race and gender
on donation practices showed that among the general
public in Maryland, black males were more than three
times less willing to be listed as donors on their driver’s
licenses than were white males, and black females were
40% less likely than white males [66]. Race explained
more variation in cadaveric donation than in living dona-
tion rates; in the latter case, concern over having a surgi-
cal procedure was the dominant factor [67]. The study
went further in exploring reasons why blacks are less
willing to donate their organs posthumously. African
Americans were more likely than whites to consider reli-
gion and spirituality extremely important in their life,
and they were more likely to be concerned about mistrust
or discrimination. Spirituality and mistrust accounted for
a large percentage of the difference between African
Americans and whites in willingness to donate organs.
The implication is that interventions that address reli-
gious concerns or allay mistrust might help narrow the
racial gap in donation rates, thereby making more organs
available and expanding the genetic pool of available
kidneys. In turn, the gap between renal transplantation
rates in African Americans and whites might narrow.
Summary
The case presented today is a vivid representation of
the epidemic of chronic kidney disease that is dispropor-
tionately affecting ethnic minorities in the United States
and the challenges that occur in achieving optimal out-
comes for such patients. The excess risk of chronic kidney
disease among minorities, particularly African Ameri-
cans, is multifactorial and due to potentially modifiable
risk factors such as access to care, improved health be-
haviors, and better overall clinical management. Although
African Americans on dialysis have better survival rates
than do whites for unclear reasons, evidence suggests that
blacks receive peritoneal dialysis less often, receive inade-
quate doses of dialysis, and are less likely to undergo trans-
plantation. Promotion of social justice, including fair alloca-
tion of health resources, is one of the important principles
of medical professionalism embraced by physicians [68].
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Physicians who care for patients with chronic kidney
disease should try to understand the barriers that lead
to inequalities in care. We should work to narrow and
ultimately eliminate these disparities.
QUESTIONS AND ANSWERS
Dr. Nicolaos E. Madias (Dean ad interim, Tufts Uni-
versity School of Medicine, Boston, Massachusetts): Could
you please comment on what is known about genetic
factors that predispose blacks to renal disease?
Dr. Powe: A few studies have found families in which
ESRD or chronic renal disease is prevalent [9, 10]. Some
small studies have tried to identify whether genes confer
this excess risk [11]. I think that the search for genes
that explain this higher incidence across the population
has not been as fruitful as one might have hoped. I person-
ally believe there might be genetic factors in some families
that drive this but, as I mentioned, another body of evi-
dence suggests that nonbiologic factors, including social
and economic status and health behaviors, account for
the higher incidence. I think future studies will reveal
that both genetic background and nonbiologic factors
determine risk of renal disease in blacks and whites.
Dr. Madias: I was surprised and fascinated by the fact
that despite delayed referral to nephrologists, correction
for case mix, and perceived inadequate dose of dialysis,
blacks have a survival advantage on dialysis compared
to whites. It is a striking finding that cries for an explana-
tion. How rigorously has this issue been examined? Are
there differences in variables such as hematocrit, reuse
of dialyzers, secondary hyperparathyroidism, or cardio-
vascular or other medication use between the two groups?
Dr. Powe: Unfortunately, little work has been done
that would answer your question. But with regard to
treatment for anemia, in the early days when erythropoi-
etin was first approved by the Food and Drug Adminis-
tration for the treatment of anemia in ESRD, there were
initial differences in access to erythropoietin therapy.
It’s interesting that hematocrit levels among blacks who
begin dialysis are lower than those for whites [69]. That
discrepancy in hematocrit level is true in the general
population as well, likely because of genetic factors. Rel-
atively little is known about the association between
renal disease and hyperparathyroidism; those areas are
ripe for investigation. I think that looking at those areas
might provide some insight into this paradoxic finding
of greater survival of African Americans than whites in
the dialysis population.
Dr. John T. Harrington (Division of Nephrology,
Tufts-New England Medical Center): Has any national
group, the National Kidney Foundation, for instance,
taken on the challenge of increasing organ donation
among blacks?
Dr. Powe: Yes, in fact the 1990s witnessed increasing
organ donation rates among blacks not only for kidneys
but for all organs. Dr. Clive Callender at Howard Univer-
sity School of Medicine has been a leader in this effort.
The National Kidney Foundation also is making an effort
to increase organ donation rates. Some experimental stud-
ies have been funded by the Federal government to look
at interventions for increasing organ donation. However,
many of the efforts may be misguided and ineffective
without the type of information that gets at the underly-
ing reasons why people are not willing to donate organs.
Dr. Harrington: Have studies comparable to the kind
you’ve carried out been done in countries that have na-
tional health care systems? I’m thinking specifically of
the United Kingdom. The health care disparity in London
with people from around the world is enormous. That
locale would be a good place to do comparable studies.
Dr. Powe: As would a locale where there is a National
Health Insurance system that guarantees a minimum level
of health care to all persons. I think it would be interest-
ing to determine whether these disparities exist among
different ethnic populations in other countries.
Dr. Harrington: Finally, just a comment on your com-
ments regarding the current epidemic of chronic kidney
disease. My professional career extends back before the
beginning of your time line. I see this epidemic of chronic
kidney disease as a result of our partial success. That is,
prior to the beginning of the Medicare End-Stage Renal
Disease System in 1971, virtually all patients died and
thus did not “accumulate” on dialysis as patients do at
present. We have had a partial success, not a complete
success yet.
Dr. Andrew S. Levey (Division of Nephrology, Tufts-
New England Medical Center, Boston, Massachusetts):
You mentioned the disproportionate burden of chronic
kidney disease in blacks and other ethnic minorities. Do
you think it’s appropriate to consider ethnic minorities
as high-risk groups for renal disease and thus deserving
of efforts for early detection? Second, what do we know
about proteinuria and screening for proteinuria in black
versus white populations?
Dr. Powe: The National Institute of Diabetes, Diges-
tive and Kidney Diseases launched a new National Kid-
ney Disease Education Program, an effort to improve
public education about kidney disease. In fact, the first
priority for outreach efforts is among African American
communities. Pilot studies have begun in four communi-
ties throughout the United States: Atlanta, Detroit, Bal-
timore, and Cleveland. These studies will look at what
types of public education programs can increase aware-
ness of the need for adequate care for renal disease.
Hopefully those efforts will expand to a national level.
The issue of proteinuria is difficult, because we don’t
have enough information. We know that people who
have proteinuria are more likely to develop renal disease.
What we don’t know is how we should intervene in that
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regard. We have some clear indications for diabetics and
emerging evidence for non-diabetics that ACE inhibitors
and angiotensin receptor blockers can delay progression
[70, 71]. Whether one should screen the general popula-
tion for proteinuria is unclear.
Dr. Madias: It would be of interest for us to know
whether the panel of disparities you described in adults
with chronic kidney disease extends to the pediatric and
adolescent population. Are such data available?
Dr. Powe: Data on use of both peritoneal dialysis and
renal transplantation among ethnic minorities also apply
to the pediatric population [36, 61]. The latter is impor-
tant because children are much more likely to get kidney
transplants. In fact, that’s part of the criteria for allocation.
African American children’s names do not appear on
wait-lists as often as white. I think we know far less
about the pediatric population than we should. In African
American adolescents, we would probably find more hy-
pertension and thus early development of ESRD.
Dr. Samina Khan (Division of Nephrology, Tufts-New
England Medical Center): There are two messages in
your talk. Number one is the epidemic of chronic kidney
disease, and the other is the health care disparity within
that. My first question is, what is the number one inter-
vention you can use to reduce the epidemic? Should we
reorder the Federal and state budgets to target preven-
tive medicine? My second question is about the disparity
in health care. One issue that has not been rigorously
studied is the mistrust of the black population toward
health care providers and the lack of enthusiasm of some
of those providers in caring for ethnic populations.
Dr. Powe: Your first question is whether our current
efforts are misguided as to where we allocate resources
in the health care system. I believe that societal and
political considerations have prompted us to shift our
resources toward preventing disease. A good example
is the prevention of acute infectious diseases, as in the
polio epidemic of the early 1950s. Our money now should
be spent to prevent chronic diseases as well as acute,
and I believe that physicians should be part of that.
But our limited resources in health care, or at least a
perception of limited resources, have not been directed
toward prevention of renal disease to date.
The second issue that you mentioned relates to cul-
tural differences, issues like mistrust of the health care
system that can influence our ability to improve care,
and how we might modify them. We need to figure out
what we can do to engage patients better so they don’t
mistrust the health care system or providers.
Dr. Annamaria Kausz (Division of Nephrology, Tufts-
New England Medical Center): You had alluded that
racial concordance might result in increased trust and
possibly better physician/patient relationships, which
then would hopefully lead to better adherence to recom-
mended care. One suggestion that you made was that
we should encourage the development of physicians in
racial minority groups to increase their number and pro-
mote their development through medical school and in
their career. Would this really help? Is anything known
about how often individuals from underprivileged or mi-
nority settings who go to universities, medical schools,
and graduate schools end up back in the communities
that they came from?
Dr. Powe: You ask whether training more individuals
from ethnic minority backgrounds will help improve this
situation by providing doctors who can relate more to
the population of patients that they’re treating. That is
a goal we should strive for. The Association of American
Medical Colleges has been a leader in trying to create
a more diverse group of physicians. In fact, evidence
does indicate that individuals from underprivileged and
minority backgrounds deliver care to minority populations
[72–74]. One study in the mid-1980s by Dr. Steven Keith
showed that physicians who were part of ethnic minorit-
ies in the UCLA School of Medicine Class of 1975 were
more likely than their white counterparts to practice in
areas that were underserved, such as those with Medicaid
patients and larger minority populations. Recent work
by Dr. Ernest Moy has confirmed that on a national
scale, minority physicians are likely to return and provide
care to underprivileged groups [73].
Dr. Bertrand L. Jaber (Division of Nephrology, Tufts-
New England Medical Center): My question pertains to
the disparity in outcomes between African American and
white ESRD patients. You said that when a black patient
enters the ESRD program, equal access through Medi-
care leads to a higher rate of interventions, specifically,
cardiovascular procedures. Do you think that some of
these disparities are due to a higher procedure rate among
blacks versus whites, and that these procedures confer
a survival advantage?
Dr. Powe: That’s an interesting issue that I’ve not
thought about. The fact that more African Americans
who develop ESRD might have more access to cardio-
vascular procedures that produce better survival rates
hasn’t been looked at explicitly. It’s plausible but I’m
not sure that would be the reason; it’s something that
should be looked at, that is, whether treatment differ-
ences versus health status differences drive that disparity.
Dr. Klemens B. Meyer (Division of Nephrology, Tufts-
New England Medical Center): You commented that the
Medicare ESRD entitlement had erased one of the barri-
ers to health care and eliminated some disparities. In
your case presentation, you noted that the patient re-
turned to work on days on which he did not undergo
dialysis until he received notification of his eligibility for
both Medicare and disability payments. That’s very inter-
esting. Is there any information about disparities in reha-
bilitation in ESRD across ethnic and racial groups?
Dr. Powe: I’m not aware of any work that’s been done
to describe disparities, for example, in returning to work
after developing ESRD or after receiving disability
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payments in association with kidney disease. Certainly,
that is an area that’s fascinating. One could look at
whether there are behavioral or cultural issues that drive
disparities in this instance.
Dr. Jaber: Emerging literature in the lay press has
described people relying on disabilities because they can’t
get decent jobs. We’ve encountered this in our dialysis
patients. Sometimes we’ve been a bit embarrassed about
signing the disability forms, but it seemed the right thing
to do. I wonder whether we’re at the leading edge of a
not-very-good curve.
Dr. Powe: You are describing the highly contested
hypothesis that availability of disability insurance influ-
ences people’s work because of entitlement. There’s evi-
dence on both sides not only in kidney disease but in
other diseases as well.
Dr. Meyer: It strikes me that the epidemic of chronic
kidney disease has hit the African American population
disproportionately. We’ve gone from a situation in which
everybody who had chronic renal disease died to a situa-
tion in which, for some communities, this is a prominent
feature of life. Is there any information about how
chronic kidney disease has affected these communities?
Or whether there’s a difference in response across differ-
ent communities?
Dr. Powe: I’m unaware of work done in that area,
but the National Kidney Disease Education Program is
trying to gather systematic data through the use of focus
groups to determine how kidney disease is affecting mi-
nority communities.
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